243 related articles for article (PubMed ID: 19499381)
1. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
Rodriguez-Monguio R; Seoane-Vazquez E
AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
[TBL] [Abstract][Full Text] [Related]
2. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
3. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
4. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
[TBL] [Abstract][Full Text] [Related]
5. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
6. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
7. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
8. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
9. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic agents marketed in 1995.
Hussar DA
Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic agents marketed in 1993.
Hussar DA
Pa Med; 1994 Apr; 97(4):12-6. PubMed ID: 8008381
[TBL] [Abstract][Full Text] [Related]
12. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
[TBL] [Abstract][Full Text] [Related]
13. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
Hogan GF
Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
[TBL] [Abstract][Full Text] [Related]
14. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
15. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
[TBL] [Abstract][Full Text] [Related]
16. Recent trends in brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R
J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
[TBL] [Abstract][Full Text] [Related]
17. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
18. New therapeutic agents marketed in 1993.
Hussar DA
Pa Med; 1994 Jun; 97(6):22-3. PubMed ID: 8065777
[TBL] [Abstract][Full Text] [Related]
19. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
20. New therapeutic agents marketed in 1993.
Hussar DA
Pa Med; 1994 May; 97(5):12-7. PubMed ID: 8036027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]